{"disease":{"id":"treatment-of-uncomplicated-plasmodium-falciparum-malaria","name":"treatment of uncomplicated plasmodium falciparum malaria"},"drugs":{"marketed":[{"drug_id":"artesunate-amodiaquine-as-aq","indication_name":"Treatment of acute, uncomplicated Plasmodium falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"artesunate-amodiaquine (AS-AQ)","company_name":"Yale University","drug_phase":"marketed","molecular_target":"Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase","drug_class":"Artemisinin derivative + aminoquinoline antimalarial combination","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}